A select few for-profit labs in India have been allowed to start running COVID-19 tests, albeit with a price cap and a shortage of tests kits to run them with.
Listed hospital and outpatient service operators across the globe have adjusted 2020 guidance, issued profit warnings and cancelled dividends as elective and private activity plummets due to the COVID-19 outbreak. Operators more focused on publicly-funded work seem to be doing slightly better.
Hospital and lab procurement has been hit hard by the COVID-19 outbreak, with four-fold price and an uptick in ordering from China, industry sources tell HBI.
COVID-19 is forcing European laboratories to re-think where they test patients. Some are working with authorities to set up new ‘drive-through’ testing points, while others have closed more than half of their drawing points.
Public elective surgeries are being cancelled across Europe, replaced in part by additional for-profit outsourcing, and governments are buying private hospital capacity for an expected flood of COVID-19 cases. In some countries, the stop on electives is across both public and private sectors. HBI investigates.
In the second of our two-part deep dive into how COVID-19 is hitting healthcare markets across EMEA, we ask how hospitals are coping with spiralling staff sickness and a flood of patients, and whether the care and dialysis sectors can stay afloat given the risk the virus poses to their most vulnerable patients.
Listed Brazilian dental benefits provider Odontoprev revealed a solid FY 2019 performance during an analyst call this week as it published its annual report and Q4 results.
In the latest in a long line of scandalous revelations to hit the UAE's largest for-profit healthcare provider, NMC Health has revealed it has uncovered $2.7bn of debt which was hidden from its board, and used for unknown purposes - bringing its borrowings to a whopping $5bn.
With the help of a results-based financing mechanism, Mexico's largest specialised diabetes provider Clínicas del Azúcar has doubled its number of patients from the poorest segments of society and tells HBI it can now double the locations for potential clinics. We speak to its CEO and the co-creator of 'social impact incentives' about how to monetise extra value in impact investing.
Dr Markus Hamm, the former CEO of family-owned German hospital group Schoen-Kliniken, has a new role as group CEO of German ophthalmology group Ober Scharrer. What does this say about the company’s plans?
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
